(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Greenrose Acquisition Corp., Castle Biosciences, and Glory Star New Media Group Holdings Limited.

The three biggest losers today are Interpace Biosciences, HOOKIPA Pharma, and Genprex.

Winners today

1. Greenrose Acquisition Corp. (GNRSW) – 64.2%

NASDAQ ended the session with Greenrose Acquisition Corp. jumping 64.2% to $0.01 on Friday while NASDAQ dropped 0.13% to $13,660.72.

Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $0.01 at 17:32 EST, way under its 52-week low of $0.01.

More news about Greenrose Acquisition Corp..

2. Castle Biosciences (CSTL) – 52.19%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences jumping 52.19% to $20.21 on Friday, following the last session’s downward trend. NASDAQ slid 0.13% to $13,660.72, after two sequential sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.33%.

Yearly Top and Bottom Value

Castle Biosciences’s stock is valued at $20.21 at 17:32 EST, way under its 52-week high of $36.10 and way higher than its 52-week low of $9.26.

Moving Average

Castle Biosciences’s worth is higher than its 50-day moving average of $19.69 and way below its 200-day moving average of $22.85.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 1416.7% and a negative 27.3%, respectively.

Sales Growth

Castle Biosciences’s sales growth is 26.8% for the present quarter and 20.2% for the next.

More news about Castle Biosciences.

3. Glory Star New Media Group Holdings Limited (GSMGW) – 51.22%

Glory Star New Media Group Holdings Limited provides advertisement and content production services in China. The company also engages in the mobile and online advertising, digital media, and entertainment businesses. In addition, it offers CHEERS app, an e-commerce platform, which provides online store, live streaming, and online games, as well as online short videos, variety shows, and dramas. Glory Star New Media Group Holdings Limited was founded in 2016 and is headquartered in Beijing, China.

NASDAQ ended the session with Glory Star New Media Group Holdings Limited jumping 51.22% to $0.01 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Glory Star New Media Group Holdings Limited has a trailing twelve months EPS of $0.54.

PE Ratio

Glory Star New Media Group Holdings Limited has a trailing twelve months price to earnings ratio of 0.02. Meaning, the purchaser of the share is investing $0.02 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.93%.

Yearly Top and Bottom Value

Glory Star New Media Group Holdings Limited’s stock is valued at $0.01 at 17:32 EST, way under its 52-week low of $0.01.

More news about Glory Star New Media Group Holdings Limited.

4. Kodak (KODK) – 16.01%

Eastman Kodak Company provides hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through four segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment offers digital offset plate and computer-to-plate imaging solutions to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The Digital Printing segment provides electrophotographic printing solutions, such as The ASCEND and NEXFINITY printers; prosper products, including the PROSPER 6000 Press, PROSPER Writing Systems, PROSPER press systems, and PROSPER components; versamark products; and PRINERGY workflow production software. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, and advanced materials and functional printing businesses. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company engages in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.

NYSE ended the session with Kodak jumping 16.01% to $5.87 on Friday while NYSE jumped 0.19% to $15,671.63.

Earnings Per Share

As for profitability, Kodak has a trailing twelve months EPS of $0.58.

PE Ratio

Kodak has a trailing twelve months price to earnings ratio of 10.12. Meaning, the purchaser of the share is investing $10.12 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.5%.

Moving Average

Kodak’s value is way higher than its 50-day moving average of $4.31 and way above its 200-day moving average of $4.13.

More news about Kodak.

5. KalVista Pharmaceuticals (KALV) – 14.97%

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with KalVista Pharmaceuticals rising 14.97% to $10.29 on Friday, following the last session’s downward trend. NASDAQ slid 0.13% to $13,660.72, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, KalVista Pharmaceuticals has a trailing twelve months EPS of $-3.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.24%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

KalVista Pharmaceuticals’s EBITDA is -5.87.

Yearly Top and Bottom Value

KalVista Pharmaceuticals’s stock is valued at $10.29 at 17:32 EST, way under its 52-week high of $17.06 and way higher than its 52-week low of $4.12.

More news about KalVista Pharmaceuticals.

6. Akerna Corp. (KERNW) – 14.8%

NASDAQ ended the session with Akerna Corp. rising 14.8% to $0.03 on Friday while NASDAQ dropped 0.13% to $13,660.72.

Yearly Top and Bottom Value

Akerna Corp.’s stock is valued at $0.03 at 17:32 EST, higher than its 52-week high of $0.03.

More news about Akerna Corp..

7. KLX Energy Services Holdings (KLXE) – 14.67%

KLX Energy Services Holdings, Inc. provides drilling, completions, production, and well intervention services and products to the onshore oil and gas producing regions of the United States. The company operates through three segments: Southwest, Rocky Mountains, and Northeast/Mid-Con. It provides directional drilling services; and downhole navigational and rental tools businesses and support services, including well planning, site supervision, accommodation rentals, and other drilling rentals. The company also offers coiled tubing and nitrogen services; pressure control products and services; wellhead and hydraulic fracturing rental products and services; flowback and testing services; and wireline services. In addition, it offers toe sleeves; wet shoe cementing bypass subs; composite plugs; dissolvable plugs; liner hangers; stage cementing tools, inflatables, float and casing equipment; retrievable completion tools; cementing products and services; thru-tubing technologies and services; rig assist snubbing services; and acidizing and pressure pumping services. Further, the company provides production services comprising maintenance-related intervention services; production blow out presenters; mechanical wireline services; slick line services; hydro-testing services; premium tubulars; and other specialized production tools. It also provides intervention services consisting of technicians and equipment that are focused on providing customers engineered solutions to downhole complications. The company offers a range of technical services, and related tools and equipment to companies engaged in the exploration and development of North American onshore conventional and unconventional oil and natural gas reserves. KLX Energy Services Holdings, Inc. was incorporated in 2018 and is headquartered in Houston, Texas.

NASDAQ ended the session with KLX Energy Services Holdings rising 14.67% to $10.24 on Friday while NASDAQ dropped 0.13% to $13,660.72.

Earnings Per Share

As for profitability, KLX Energy Services Holdings has a trailing twelve months EPS of $2.37.

PE Ratio

KLX Energy Services Holdings has a trailing twelve months price to earnings ratio of 4.32. Meaning, the purchaser of the share is investing $4.32 for every dollar of annual earnings.

Yearly Top and Bottom Value

KLX Energy Services Holdings ‘s stock is valued at $10.24 at 17:32 EST, way below its 52-week high of $18.63 and way above its 52-week low of $3.64.

Volume

Today’s last reported volume for KLX Energy Services Holdings is 372648 which is 56.74% above its average volume of 237744.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 131.4% and 173.8%, respectively.

More news about KLX Energy Services Holdings .

8. Riot Blockchain (RIOT) – 13.18%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain rising 13.18% to $15.32 on Friday while NASDAQ fell 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-5.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.

Moving Average

Riot Blockchain’s worth is way above its 50-day moving average of $11.12 and way higher than its 200-day moving average of $7.55.

Volume

Today’s last reported volume for Riot Blockchain is 37655400 which is 59.13% above its average volume of 23661800.

Sales Growth

Riot Blockchain’s sales growth is 19.5% for the ongoing quarter and 70.8% for the next.

Volatility

Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was 4.79%, 1.44%, and 5.11%.

Riot Blockchain’s highest amplitude of average volatility was 5.04% (last week), 3.42% (last month), and 5.11% (last quarter).

More news about Riot Blockchain.

9. Canaan (CAN) – 10.94%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan rising 10.94% to $2.49 on Friday, after two successive sessions in a row of losses. NASDAQ dropped 0.13% to $13,660.72, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.4%.

Volatility

Canaan’s last week, last month’s, and last quarter’s current intraday variation average was 1.76%, 0.81%, and 4.38%.

Canaan’s highest amplitude of average volatility was 3.24% (last week), 3.84% (last month), and 4.38% (last quarter).

Volume

Today’s last reported volume for Canaan is 4152300 which is 69.69% above its average volume of 2446940.

More news about Canaan.

10. Canopy Growth (CGC) – 10.66%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 10.66% to $0.47 on Friday, after four sequential sessions in a row of losses. NASDAQ slid 0.13% to $13,660.72, after two consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-5.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

Sales Growth

Canopy Growth’s sales growth is negative 16.8% for the ongoing quarter and negative 14.9% for the next.

Previous days news about Canopy Growth

• : analyst cuts canopy growth price target to $0. According to MarketWatch on Wednesday, 5 July, "Eight Capital analyst Ty Collin on Wednesday cut his price target for Canadian cannabis company Canopy Growth Corp. to $0 from C$1.75 ($1.32) a share and reiterated a sell rating on the stock."

More news about Canopy Growth.

Losers Today

1. Interpace Biosciences (IDXG) – -15.86%

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

NASDAQ ended the session with Interpace Biosciences dropping 15.86% to $0.88 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Interpace Biosciences has a trailing twelve months EPS of $-0.89.

Sales Growth

Interpace Biosciences’s sales growth for the current quarter is negative 23.2%.

Volume

Today’s last reported volume for Interpace Biosciences is 8848 which is 39.88% above its average volume of 6325.

More news about Interpace Biosciences.

2. HOOKIPA Pharma (HOOK) – -10.03%

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

NASDAQ ended the session with HOOKIPA Pharma falling 10.03% to $0.78 on Friday while NASDAQ dropped 0.13% to $13,660.72.

Earnings Per Share

As for profitability, HOOKIPA Pharma has a trailing twelve months EPS of $-0.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.58%.

Sales Growth

HOOKIPA Pharma’s sales growth for the current quarter is 77.3%.

Moving Average

HOOKIPA Pharma’s worth is way below its 50-day moving average of $1.20 and way below its 200-day moving average of $1.05.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 8.7% and 24%, respectively.

Yearly Top and Bottom Value

HOOKIPA Pharma’s stock is valued at $0.78 at 17:32 EST, way under its 52-week high of $2.05 and way higher than its 52-week low of $0.68.

More news about HOOKIPA Pharma.

3. Genprex (GNPX) – -7.78%

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NASDAQ ended the session with Genprex dropping 7.78% to $0.85 on Friday, after two sequential sessions in a row of losses. NASDAQ slid 0.13% to $13,660.72, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Genprex has a trailing twelve months EPS of $-0.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Genprex’s EBITDA is -2.84.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 9.1% and positive 7.7% for the next.

Moving Average

Genprex’s worth is higher than its 50-day moving average of $0.84 and way under its 200-day moving average of $1.15.

Yearly Top and Bottom Value

Genprex’s stock is valued at $0.85 at 17:32 EST, way under its 52-week high of $2.67 and way higher than its 52-week low of $0.72.

More news about Genprex.

4. Esports Entertainment Group (GMBL) – -7.14%

Esports Entertainment Group, Inc. operates as an online gambling company in Canada. The company offers esports entertainment, esports wagering, and iGaming and traditional sports betting services, as well as professional and amateur esports events. It also operates vie.gg, an online esports wagering website. The company was formerly known as VGambling, Inc. and changed its name to Esports Entertainment Group, Inc. in May 2017. Esports Entertainment Group, Inc. was incorporated in 2008 and is based in Birkirkara, Malta.

NASDAQ ended the session with Esports Entertainment Group sliding 7.14% to $1.04 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Esports Entertainment Group has a trailing twelve months EPS of $11.86.

PE Ratio

Esports Entertainment Group has a trailing twelve months price to earnings ratio of 0.09. Meaning, the purchaser of the share is investing $0.09 for every dollar of annual earnings.

More news about Esports Entertainment Group.

5. Gamida Cell Ltd. (GMDA) – -6.98%

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

NASDAQ ended the session with Gamida Cell Ltd. falling 6.98% to $1.60 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Gamida Cell Ltd. has a trailing twelve months EPS of $-1.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1666.05%.

Yearly Top and Bottom Value

Gamida Cell Ltd.’s stock is valued at $1.60 at 17:32 EST, way under its 52-week high of $3.66 and way higher than its 52-week low of $0.56.

Moving Average

Gamida Cell Ltd.’s value is way below its 50-day moving average of $1.91 and under its 200-day moving average of $1.61.

Volume

Today’s last reported volume for Gamida Cell Ltd. is 3373780 which is 36.59% below its average volume of 5320960.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Gamida Cell Ltd.’s EBITDA is -5.12.

More news about Gamida Cell Ltd..

6. Hall of Fame Resort & Entertainment Company (HOFV) – -6.87%

Hall of Fame Resort & Entertainment Company, a resort and entertainment company, doing business as the Pro Football Hall of Fame. It owns the premier sports, entertainment, and media enterprise surrounding the Pro Football Hall of Fame in Canton, Ohio. The company was founded in 2015 and is headquartered in Canton, Ohio.

NASDAQ ended the session with Hall of Fame Resort & Entertainment Company sliding 6.87% to $8.76 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Hall of Fame Resort & Entertainment Company has a trailing twelve months EPS of $-9.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.57%.

Moving Average

Hall of Fame Resort & Entertainment Company’s value is higher than its 50-day moving average of $8.09 and way below its 200-day moving average of $10.69.

More news about Hall of Fame Resort & Entertainment Company.

7. InflaRx N.V. (IFRX) – -6.7%

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

NASDAQ ended the session with InflaRx N.V. sliding 6.7% to $3.90 on Friday while NASDAQ slid 0.13% to $13,660.72.

Earnings Per Share

As for profitability, InflaRx N.V. has a trailing twelve months EPS of $-0.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.59%.

Volume

Today’s last reported volume for InflaRx N.V. is 448898 which is 25.92% below its average volume of 605980.

More news about InflaRx N.V..

8. Greenpro Capital Corp. (GRNQ) – -6.4%

Greenpro Capital Corp. provides financial consulting and corporate services to small and medium-size businesses primarily in Hong Kong, Malaysia, and China. It operates in two segments, Service Business and Real Estate Business. The company offers business consulting and corporate advisory services, including cross-border listing advisory, tax planning, bookkeeping, advisory and transaction, record management, and accounting outsourcing services; and venture capital related education and support services. It is also involved in the acquisition and rental of real estate properties held for investment and sale; and provision of company formation advisory, company secretarial, and financial services. In addition, the company provides corporate advisory services, such as company review, bank loan advisory, and bank products analysis, as well as loan and credit, and insurance brokerage services; and wealth planning, administration, charity, tax and legal, trusteeship and risk management, investment planning and management, and business support services, as well as asset protection and management, consolidation, and performance monitoring services. The company was formerly known as Greenpro, Inc. and changed its name to Greenpro Capital Corp. in May 2015. Greenpro Capital Corp. was founded in 2013 and is headquartered in Hung Hom, Hong Kong.

NASDAQ ended the session with Greenpro Capital Corp. falling 6.4% to $1.61 on Friday, after three successive sessions in a row of losses. NASDAQ slid 0.13% to $13,660.72, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Greenpro Capital Corp. has a trailing twelve months EPS of $-0.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.16%.

More news about Greenpro Capital Corp..

9. Huize Holding Limited (HUIZ) – -5.93%

Huize Holding Limited, together with its subsidiaries, offers insurance brokerage services in the People's Republic of China. It provides life and health insurance products, such as critical illness, illness and disease, and term life and whole life insurance products; and property and casualty insurance products, including travel, individual casualty, and corporate liability insurance products. The company offers its products through internet and mobile internet channels. It also provides technology development and Internet information consulting services; and management, marketing, investment, and financial consulting services. Huize Holding Limited was founded in 2006 and is headquartered in Shenzhen, the People's Republic of China.

NASDAQ ended the session with Huize Holding Limited dropping 5.93% to $1.27 on Friday while NASDAQ fell 0.13% to $13,660.72.

Earnings Per Share

As for profitability, Huize Holding Limited has a trailing twelve months EPS of $-0.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.24%.

More news about Huize Holding Limited.

10. GDS Holdings Limited (GDS) – -4.72%

GDS Holdings Limited, together with its subsidiaries, develops and operates data centers in the People's Republic of China. The company provides colocation, managed hosting, and managed cloud services, as well as consulting services to the cloud, internet and banking industries. The company serves cloud service providers, Internet companies, financial institutions, telecommunications and IT service providers, and large domestic private sector and multinational corporations. The company has a strategic partnership with GIC Private Limited to develop and operate hyperscale build-to-suit data centers in China. GDS Holdings Limited was founded in 2001 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with GDS Holdings Limited dropping 4.72% to $10.10 on Friday, after two consecutive sessions in a row of losses. NASDAQ slid 0.13% to $13,660.72, after two successive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, GDS Holdings Limited has a trailing twelve months EPS of $-0.97.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.6%.

More news about GDS Holdings Limited.

Stay up to date with our winners and losers daily report